Itafos Inc. (CVE:IFOS - Get Free Report)'s stock price traded up 12% on Thursday . The company traded as high as C$2.43 and last traded at C$2.43. 100,738 shares changed hands during mid-day trading, an increase of 349% from the average session volume of 22,444 shares. The stock had previously closed at C$2.17.
Itafos Stock Down 0.9 %
The company's 50 day simple moving average is C$2.05 and its 200-day simple moving average is C$1.82. The company has a current ratio of 2.66, a quick ratio of 0.73 and a debt-to-equity ratio of 31.70. The firm has a market cap of C$304.92 million, a P/E ratio of 31.16 and a beta of -0.95.
About Itafos
(
Get Free Report)
Itafos Inc operates as a phosphate and specialty fertilizer company. It operates through Conda, Arrais, and Development and Exploration segments. The company produces and sells monoammonium phosphate (MAP), MAP with micronutrients, superphosphoric acid, merchant grade phosphoric acid, ammonium polyphosphate, hydrofluorosilicic acid, direct application phosphate rock, single superphosphate (SSP), SSP with micronutrients, and sulfuric acid.
Featured Stories
Before you consider Itafos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Itafos wasn't on the list.
While Itafos currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
